Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Research Article

Validated Microemulsion Liquid Chromatography-Fluorescence Method for the Quantification of Duloxetine and its Two Main Metabolites in Plasma: Application to Clinical Pharmacokinetic Studies

Author(s): Raniah Al-Shalabi, Mohamed Hefnawy*, Haitham Alrabiah, Haya Al-Johar, Mostafa Mohammed, Mohammed Alanazi, Abdulrahman Almehizia, Mohammed Abounassif and Yousef Bin Jardan

Volume 15, Issue 4, 2019

Page: [399 - 411] Pages: 13

DOI: 10.2174/1573412915666181224123749

Price: $65

Abstract

Background: Duloxetine (DL) is a selective serotonin and norepinephrine reuptake inhibitor. The drug is used in the treatment of major depression, anxiety, pain related to diabetic peripheral neuropathy and stress urinary incontinence.

Objective: This study described, for the first time, the development and validation of a highly selective and sensitive microemulsion liquid chromatography-fluorescence (MELC-FL) method with low environmental pollution and without extraction steps for the simultaneous quantification of DL, and its two main metabolites; 5-hydroxy-6-methoxy duloxetine (5-HDL) and 4-hydroxy duloxetine glucuronide (4- HDLG) in plasma.

Methods: The studied analytes and methyl paraben (an internal standard) were detected using excitation and emission wavelengths of 280 and 340 nm, respectively. The analysis was performed on Water Symmetry C18 analytical column (100 Å, 150 mm x 3.9 mm, 5 µm) by directly injecting the plasma after appropriate dilution with microemulsion mobile phase. Total analytical run time was 4 min.

Results: The MELC-FL method was statistically validated according to the FDA guidelines for bioanalytical methods for linearity, accuracy, precision, specificity, robustness, and stability. Linear calibration plots were achieved in the ranges of 25-1200 ng/mL for DL and 50-1500 ng/mL for 5-HDL and 4- HDLG (r2 ≥ 0.997) in rat plasma. The intra- and inter- assay precisions and accuracy were acceptable. The overall recoveries of DL and its two main metabolites from rat plasma were between 97.12% and 103.12% with an RSD value between 0.34% and 4.57%.

Conclusion: The present study supports the possible use of the microemulsion mobile phase in LC as a “greener ” mobile phase. The developed method offered an advantage in the form of direct analysis of biological samples after appropriate dilution with eco-friendly microemulsion mobile phase, which decreased the possibility of sample loss during analysis. The developed assay was successfully applied in a pharmacokinetic study and it established the applicability of the method for the determination of concentration-time profiles of DL and its two main metabolites in rat plasma after systemic administration.

Keywords: Microemulsion liquid chromatography, duloxetine, metabolites, rat plasma, pharmacokinetic study, metabolites.

« Previous
Graphical Abstract

[1]
Stahl, M.; Lee-Zimmerman, C.; Cartwright, S.; Ann Morrissette, D. Serotonergic drugs for depression and beyond. Curr. Drug Targets, 2013, 14, 578-585.
[2]
Bandelow, B.; Sher, L.; Bunevicius, R.; Hollandar, E.; Kasper, S.; Zohar, J.; Moller, H. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract., 2013, 16, 77-84.
[3]
Cuijpers, P.; Sijbrandij, M.; Koole, S.; Andersson, G.; Beekman, A.; Reynolds, C. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry, 2013, 12, 137-148.
[4]
Cuijpers, P.; Sijbrandij, M.; Koole, S.; Andersson, G.; Beekman, A.; Reynolds, C. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry, 2014, 13, 56-67.
[5]
Boulenger, J.; Loft, H.; Olsen, C. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int. Clin. Psychopharmacol., 2014, 29, 138-149.
[6]
Westanmo, A.D.; Gayken, J.; Haight, R. Duloxetine: a balanced and selective serotonin-reuptake inhibitor. Am. J. Health Syst. Pharm., 2005, 62, 2481-2490.
[7]
Lantz, R.; Gillespie, T.; Rash, T.; Kuo, F.; Skinner, M.; Kuan, H.; Knadler, M. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos., 2003, 31, 1142-1150.
[8]
Siddiqui, M.; AlOthman, Z.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10, 1409-1421.
[9]
AlOthman, Z.; Rahman, N.; Siddiqui, M. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Rev. Adv. Sci. Eng., 2013, 2, 155-166.
[10]
Rahman, N.; Azmi, S.; Wu, H. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11, 69-74.
[11]
Laha, T.; Mishra, G.; Sen, S. High-performance liquid chromatographic analysis of duloxetine and Its metabolites in rat and characterization of metabolites in plasma, urine, feces and bile through retro-synthesis followed by NMR and MS study. Int. J. Pharm. Sci. Drug Res., 2013, 5, 70-77.
[12]
Mercoloni, L.; Mandrioli, R.; Cazzolla, R.; Amore, M.; Raggi, M. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure. J. Chromatogr. B, 2007, 856, 81-87.
[13]
Johnson, J.; Oldham, S.; Lantz, R.; Delong, A. High performance liquid chromatographic method for the determination of duloxetine and desmethyl duloxetine in human plasma. J. Liq. Chromatogr. Relat. Technol., 1996, 19, 1631-1641.
[14]
Thejaswini, J.; Gurupadayya, B.; Ranjith, K. Quantitative determination of duloxetine HCl in human plasma by GC-FID method. Int. J. Pharm. Pharm. Sci., 2013, 5, 405-408.
[15]
Anderson, D.; Reed, S.; Lintemoot, J.; Kegler, S.; De Quintana, S. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J. Anal. Toxicol., 2006, 30, 576-580.
[16]
Sim, J.; Kim, E.; Yang, W.; Woo, S. In, S. An LC-MS/MS method for the simultaneous determination of 15 antipsychotics and two metabolites in hair and its application to rat hair. Forensic Sci. Int., 2017, 274, 91-98.
[17]
Chae, J.; Baek, H.; Kim Sang, K.; Kang, H.; Kwon, K. Quantitative determination of duloxetine and its metabolite in rat plasma by HPLC- MS/MS. Biomed. Chromatogr., 2013, 27, 953-955.
[18]
Baek, I.; Lee, B.; Kang, W.; Kwon, K. Pharmacokinetic analysis of two different doses of duloxetine following oral administration in dogs. Drug Res., 2013, 63, 404-408.
[19]
Chandrapal, D.; Bapuji, T.; Surayanarayana, R.; Himabindu, V.; Syedba, S. Development and validation of a LC/MS/MS method for the determination of duloxetine in human plasma and its application to pharmacokinetic study. E-J. Chem., 2012, 9, 899-911.
[20]
Selvan, P.; Gowda, K.; Mandal, U.; Solomon, W.; Pal, T. Determination of duloxetine in human plasma by liquid chromatography with atmospheric pressure ionization-tandem mass spectrometry and its application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 858, 269-275.
[21]
Satonin, D.; McCulloch, J.; Kuo, F.; Knadler, M. Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of the major metabolites of duloxetine in human plasma. J. Chromatogr. B, 2007, 852, 582-589.
[22]
Ma, N.; Zhang, B.; Li, H.; Chen, B.; Xu, P.; Wang, F.; Zhu, R.; Feng, S.; Xiang, D.; Zhu, Y. Determination of duloxetine in human plasma via LC/MS and subsequent application to a pharmacokinetic study in healthy Chinese volunteers. Clin. Chim. Acta, 2007, 380, 100-105.
[23]
Musengaa, A.; Amoreb, M.; Mandriolia, R.; Kenndlerc, E.; Martino, L.; Raggi, M. Determination of duloxetine in human plasma by capillary electrophoresis with laser- induced fluorescence detection. J. Chromatogr. B, 2009, 877, 1126-1132.
[24]
Rodriguez-Mozaz, S.; Lopez de Alda, M.; Barceló, D. Advantages and limitations of on-line solid phase extraction coupled to liquid chromatography–mass spectrometry technologies versus biosensors for monitoring of emerging contaminants in water. J. Chromatogr. A, 2007, 1152, 97-115.
[25]
Al-Majed, A.; Hefnawy, M.; Mohammed, M.; Attia, S.; Lehmann, J. Selective microemulsion liquid chromatography analysis of dopaminereceptor antagonist LE300 and its N-methyl metabolite in rat sera by using a monolithic silica column. J. Chromatogr. B, 2015, 989, 104-111.
[26]
US Food and Drug Administration. Center for Drug Evaluation and Research (CDER); Guidance for Industry On Bioanalytical Method Validation, Department of Health and Human Services: Rockville, MD, 2001.
[27]
CPCSEA guidelines for laboratory animal facility Committee for the Purpose of Control and Supervision on Experiments on Animals No.13/1, 3rd Seward Road, Valmiki Nagar, Thiruvanmiyur, Chennai-600 041. Indian J. Pharmacol., 2003, 35, 257-274.
[28]
National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892. https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics Retrieved Dec., 01, 2018.
[29]
Al-Jammal, M.; Al-Ayoub, Y.; Assi, K. Development and validation of micro emulsion high performance liquid chromatography(MELC) method for the determination of nifedipine in pharmaceutical preparation. Pharm. Anal. Acta, 2015, 6, 1-5.
[30]
Mannur, V.; Patel, D.; Mastiholimath, V.; Shah, G. Selection of buffers in LC-MS/MS: an overview. Int. J. Pharm. Sci. Rev. Res., 2011, 6, 34-37.
[31]
Subirats, X.; Rosés, M.; Bosch, E. On the effect of organic solvent composition on the pH of buffered HPLC mobile phases and the pKa of analytes-a review. Separ. Purif. Rev., 2007, 36, 231-255.
[32]
Miller, J.C.; Miller, J.N. Statistics and Chemometrics for analytical chemistry, 5th ed; Tottenham: England, 2005.
[33]
Li, H.; Li, T.; Li, Y.; Shen, Y. pharmacokinetics and safety of duloxetine enteric-coated tablets in chinese healthy volunteers: a randomized, open-label, single- and multiple-dose study. Clin. Psychopharmacol. Neurosci., 2013, 11, 28-33.
[34]
Singh, R.; Shivarnna, Y.; Samdani, G.; Singh, S. Determination of Duloxetine in rat plasma for pharmacokinetic study by developing a highly sensitive method using liquid chromatography-electrospray ionization tandem mass spectrometry. Int. J. Pharm. Sci. Drug Res., 2012, 3, 97-105.
[35]
Zhao, P.K.; Cheng, G.; Tang, J.; Song, J.; Peng, W.X. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Clin. Ther., 2009, 31, 1022-1036.

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy